Test Story

By: NewsUSA

March 27, 2025 at 20:00 PM EDT

(NewsUSA) - For more details, including important safety information, on VenaSeal, visit: https://www.medtronic.com/breakfree.

Sources

Gloviczki P, Comerota AJ, Dalsing MC, et al. The care of patients with varicose veins and associated chronic venous diseases: Clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg. 2011;53(5 Suppl):2S–48S. doi: 10.1016/j.jvs.2011.01.079.

Mayo Clinic: Varicose Veinshttps://www.mayoclinic.org/diseases-conditions/varicose-veins/symptoms-causes/syc-20350643

National Heart Lung and Blood Institute: Varicose Veins https://www.nhlbi.nih.gov/health/varicose-veins

Morrison N, Gibson K, McEnroe S, et al. Randomized trial comparing cyanoacrylate embolization and radiofrequency ablation for incompetent great saphenous veins (VeClose). J Vasc Surg. 2015;61(4):985–994. doi: 10.1016/j.jvs.2014.11.071.

Proebstle T, Alm J, Dimitri S, et al. Three-year follow-up results of the prospective European multicenter cohort study on cyanoacrylate embolization for treatment of refluxing great saphenous veins. J Vasc Surg Venous Lymphat Disord. 2021;9(2):329–334. doi: 10.1016/j.jvsv.2020.05.019.

Almeida JI, Javier JJ, Mackay EG, Bautista C, Cher DJ, Proebstle TM. Thirty-sixth-month follow-up of first-in-human use of cyanoacrylate adhesive for treatment of saphenous vein incompetence. J Vasc Surg Venous Lymphat Disord. 2017;5(5):658–666. doi: 10.1016/j.jvsv.2017.03.016.

Symbol	Price	Change (%)
AMZN	227.35	+0.59 (0.26%)
AAPL	273.67	+1.48 (0.54%)
AMD	213.43	+12.37 (6.15%)
BAC	55.27	+1.01 (1.86%)
GOOG	308.61	+4.86 (1.60%)
META	658.77	-5.68 (-0.85%)
MSFT	485.92	+1.94 (0.40%)
NVDA	180.99	+6.85 (3.93%)
ORCL	191.97	+11.94 (6.63%)
TSLA	481.20	-2.17 (-0.45%)

Symbol

Price

Change (%)

AMZN

227.35

+0.59 (0.26%)

AAPL

273.67

+1.48 (0.54%)

AMD

213.43

+12.37 (6.15%)

BAC

55.27

+1.01 (1.86%)

GOOG

308.61

+4.86 (1.60%)

Test Story

More News

Recent Quotes

Information